Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis

Chest

Volumn 132, Issue 6, 2007, Pages 1949-1953

  Teirstein, Alvin S ^a,d   Machac, Josef ^a   Almeida, Orlandino ^b   Lu, Ping ^c   Padilla, Maria L ^a   Iannuzzi, Michael C ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Doshi Diagnostic Imaging Services   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d Box 1232 ^*  (United States)

Author keywords

Activity; Biopsy sites; Positron emission tomography scan; Sarcoidosis

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOIDOSIS; SPIROMETRY; THORAX RADIOGRAPHY; WHOLE BODY IMAGING;

EID: 37549040203     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1178     Document Type: Article

References (14)

1. American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755
2. Nguyen BD. F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med 2007; 32:53-54
3. O'Connell JB, Henkln RE, Robinson JA, et al. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsyproven myocarditis. Circulation 1984; 70:58-62
4. Kaira K, Ishizuka T, Yanagitani N, et al. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med 2007; 32:114-116
5. Machac J, Bacharach SL, Bateman TM, et al. Imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol 2006; 13:121-151
6. Morris JF, Koski A, Breese JD. Normal values and evaluation of forced end-expiratory flow. Am Rev Respir Dis 1975; 111:755-762
7. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218
8. Scadding JG. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. BMJ 1961; 2:1165-1172
9. Teirstein AS, Judson MA, Baughman RP, et al. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:139-146
10. Rosenbaum SJ, Lind T, Antoch G, et al. False-positive FDG PET uptake: the role of PET/CT. Eur Radiol 2006; 16:1054-1065
11. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131:1019-1027
12. Liu Q, Peng ZM, Liu QW, et al. The role of 11C-choline positron emission tomography-computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum. Chin Med J (Engl) 2006; 119:634-639
13. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47:1571-1576
14. Futamatsu H, Suzuki J, Adachi S, et al. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging 2006; 22:443-448